• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2022 年 9 月 12 日至 12 月 11 日，意大利≥60 岁人群在感染后时间的基础上，接种第二剂适应二价（原始/Omicron BA.4-5）mRNA 疫苗对重症 COVID-19 的保护作用。

Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022.

机构信息

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.

出版信息

Euro Surveill. 2023 Feb;28(8). doi: 10.2807/1560-7917.ES.2023.28.8.2300105.

DOI:10.2807/1560-7917.ES.2023.28.8.2300105
PMID:36820640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9951255/
Abstract

Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.

摘要

在接种首剂 mRNA 疫苗≥120 天以后，7-90 天内接种二价（原始/BA.4-5）mRNA 疫苗加强针，对比接种首剂 mRNA 疫苗加强针，对从未感染过的≥60 岁人群和≥6 个月前感染过的人群，有效性约为 60%。对于在更早 4-6 个月前感染的人群，相对有效性表明没有明显的额外保护作用（10%；95%CI：-44 至 44）。在最新感染后 6 个月接种第二剂加强疫苗可能是合理的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/9951255/e37ec2daff5c/2300105-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/9951255/b5244fa542e8/2300105-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/9951255/e37ec2daff5c/2300105-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/9951255/b5244fa542e8/2300105-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04fc/9951255/e37ec2daff5c/2300105-f2.jpg

相似文献

1
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022.2022 年 9 月 12 日至 12 月 11 日，意大利≥60 岁人群在感染后时间的基础上，接种第二剂适应二价（原始/Omicron BA.4-5）mRNA 疫苗对重症 COVID-19 的保护作用。
Euro Surveill. 2023 Feb;28(8). doi: 10.2807/1560-7917.ES.2023.28.8.2300105.
2
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.在意大利，60 岁及以上人群接种单剂和二价 mRNA 加强针后 4 个月内，针对奥密克戎 BA.5 感染预防重症 COVID-19 的相对有效性：一项回顾性匹配队列研究。
Lancet Infect Dis. 2023 Dec;23(12):1349-1359. doi: 10.1016/S1473-3099(23)00374-2. Epub 2023 Jul 18.
3
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023.对≥60 岁人群接种二价（原始/Omicron BA.4-5）mRNA 疫苗加强针对严重 COVID-19 的有效性：意大利，2022-2023 年，根据不同 Omicron 亚变体流行期间的日历时间和接种后时间估算
Vaccine. 2024 Oct 3;42(23):126026. doi: 10.1016/j.vaccine.2024.05.074. Epub 2024 Jun 3.
4
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.2023 年 4 月至 6 月，在 SARS-CoV-2 奥密克戎 XBB.1.5 和其他 XBB 亚谱系流行期间，二价原始/Omicron BA.4-5 mRNA 疫苗在预防 60 岁及以上人群重症 COVID-19 方面的相对有效性，意大利。
Euro Surveill. 2023 Aug;28(32). doi: 10.2807/1560-7917.ES.2023.28.32.2300397.
5
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.二价 mRNA 疫苗预防有症状的 SARS-CoV-2 感染的效果-增加社区获得检测的项目，美国，2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526-1530. doi: 10.15585/mmwr.mm7148e1.
6
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.2022 年 9 月 8 日至 11 月 30 日，IVY 网络，18 个州，免疫功能正常的年龄≥65 岁成年人中，二价 mRNA 疫苗预防 COVID-19 相关住院的早期估计效力。
MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1625-1630. doi: 10.15585/mmwr.mm715152e2.
7
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.关于二价加强针相对于单价加强针或初始疫苗接种周期在 SARS-CoV-2 疫苗功效方面的真实世界证据：叙述性综述。
Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081.
8
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.早期估计，二价 mRNA 加强针在预防免疫功能正常成年人因奥密克戎 BA.5-和 XBB/XBB.1.5 相关亚谱系导致的有症状 SARS-CoV-2 感染方面的有效性-增加社区获得检测计划，美国，2022 年 12 月至 2023 年 1 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.
9
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.COVID-19 mRNA 疫苗在奥密克戎为主导期间对免疫功能低下成年人 COVID-19 相关住院的有效性- VISION 网络，10 个州，2021 年 12 月至 2022 年 8 月。
MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1335-1342. doi: 10.15585/mmwr.mm7142a4.
10
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.2022 年 9 月至 11 月，免疫功能正常成年人中，二价 mRNA 疫苗在预防 COVID-19 相关急诊或紧急护理就诊和住院方面的早期效果估计- VISION 网络，9 个州。
MMWR Morb Mortal Wkly Rep. 2023 Mar 17;71(53):1637-1646. doi: 10.15585/mmwr.mm7153a1.

引用本文的文献

1
Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement.关于长新冠患者评估与治疗的多学科协作指南：一份概要声明
PM R. 2025 Apr 22. doi: 10.1002/pmrj.13397.
2
Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23.2022/23年VEBIS-EHR网络中两种评估秋季加强针COVID-19疫苗有效性方法的比较
Epidemiol Infect. 2025 Mar 17;153:e54. doi: 10.1017/S0950268825000317.
3
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster.

本文引用的文献

1
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.先前感染 SARS-CoV-2 和混合免疫对奥密克戎变异株和重症疾病的保护效力：系统评价和荟萃回归分析。
Lancet Infect Dis. 2023 May;23(5):556-567. doi: 10.1016/S1473-3099(22)00801-5. Epub 2023 Jan 18.
2
Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months.8个月内混合免疫与疫苗免疫对BA.5感染的稳定性。
Lancet Infect Dis. 2023 Feb;23(2):148-150. doi: 10.1016/S1473-3099(22)00833-7. Epub 2023 Jan 5.
3
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）会影响对奥密克戎BA.4/BA.5 mRNA加强针的适应性免疫反应。
J Allergy Clin Immunol. 2025 Jun;155(6):2038-2051. doi: 10.1016/j.jaci.2025.02.026. Epub 2025 Mar 3.
4
Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023.2022 年 9 月至 2023 年 8 月，芬兰≥65 岁人群中，二价加强针针对 COVID-19 重症结局的相对有效性。
Euro Surveill. 2024 Sep;29(37). doi: 10.2807/1560-7917.ES.2024.29.37.2300587.
5
Trends in Intention to Take the Second Booster COVID-19 Vaccination and Associated Factors in China: Serial Cross-Sectional Surveys.中国接种新冠病毒疫苗第二剂加强针的意愿趋势及相关因素：系列横断面调查
Vaccines (Basel). 2024 May 7;12(5):502. doi: 10.3390/vaccines12050502.
6
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.2023年10月至11月XBB.1.5毒株在欧盟/欧洲经济区国家占主导期间XBB.1.5单价新冠疫苗的有效性：一项VEBIS-EHR网络研究
Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292.
7
Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis.二价新冠疫苗的相对有效性：一项系统评价与荟萃分析
Front Med (Lausanne). 2024 Feb 7;10:1322396. doi: 10.3389/fmed.2023.1322396. eCollection 2023.
8
Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination.新冠病毒加强疫苗接种后抗SARS-CoV-2 IgA和IgG反应的动态变化及其对致命疾病的保护作用
Vaccines (Basel). 2023 Dec 21;12(1):12. doi: 10.3390/vaccines12010012.
9
Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea.在韩国，二价 mRNA 加强疫苗对 COVID-19 的有效性。
J Korean Med Sci. 2024 Jan 22;39(3):e15. doi: 10.3346/jkms.2024.39.e15.
10
Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines.对与新冠病毒变异株适配mRNA疫苗相关常见误解的回应。
Vaccines (Basel). 2024 Jan 6;12(1):57. doi: 10.3390/vaccines12010057.
BA.5 奥密克戎亚变体再感染风险、疫苗保护效力和感染严重程度：丹麦全国基于人群的研究。
Lancet Infect Dis. 2023 Feb;23(2):167-176. doi: 10.1016/S1473-3099(22)00595-3. Epub 2022 Oct 18.